Baili Pharmaceutical's BL-B01D1 Combination Therapy for Advanced Solid Tumors Receives FDA Clearance for Phase 1/2a Clinical Trial

Intelligent Finance APP News, Biokin (688506.SH) announced that its partner, Bristol-Myers Squibb, has received a notification from the U.S. Food and Drug Administration (“FDA”) that the Phase 1/2a clinical trial application for the BL-B01D1 combination therapy project for the treatment of advanced solid tumors has been approved by the FDA. BL-B01D1 is the world's first and only bispecific antibody-drug conjugate (ADC) targeting EGFR×HER3 to enter the clinical stage.